Karyopharm Therapeutics Inc expected to post a loss of $4.18 a share - Earnings Preview

Karyopharm Therapeutics

02/05/2025 14:09

Karyopharm Therapeutics Inc KPTI.OQ KPTI.O is expected to show a rise in quarterly revenue when it reports  results on May 6 (estimated) for the period ending March 31 2025

The Newton Massachusetts-based  company is expected to report a 6.4% increase in revenue to $35.242 million from $33.13 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Karyopharm Therapeutics Inc is for a loss of $4.18 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Karyopharm Therapeutics Inc is $54.00​, above​ its last closing price of $6.76. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-4.32
-3.92
-3.60
Beat
8.2
Sep. 30 2024
-3.76
-3.94
-3.90
Beat
1.1
Jun. 30 2024
-4.31
-4.48
2.25
Beat
150.2​
Mar. 31 2024
-4.93
-5.01
-4.80
Beat
4.2
​​Dec. 31 2023
-4.68
-4.65
-5.40
Missed
-16.2
Sep. 30 2023
-4.26
-4.20
-4.50
Missed
-7.1​
Jun. 30 2023
-5.26
-5.13
-4.35
Beat
15.3
Mar. 31 2023
-5.43
-5.52
-4.50
Beat
18.5

This summary was machine generated May 2 at 13:09 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)